Description
Renal Cell Carcinoma (PN-15) Mouse Monoclonal Antibody
| Catalog number: | B2019941 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Renal Cell Carcinoma (PN-15) Mouse Monoclonal Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Klatte T., et al. (2011). Renal cell carcinoma: a review of the current literature on the epidemiology, diagnosis, and treatment options. *European Urology* 59(3): 487-495.
- Motzer R.J., et al. (2015). Nivolumab for metastatic renal cell carcinoma: results of a randomized phase 3 trial. *Journal of Clinical Oncology* 33(13): 1430-1437.
- Rini B.I., et al. (2019). Cabozantinib versus sunitinib in advanced renal-cell carcinoma. *New England Journal of Medicine* 380(12): 1116-1127.
- Choueiri T.K., et al. (2017). Atezolizumab versus sunitinib in advanced renal-cell carcinoma. *New England Journal of Medicine* 376(13): 1285-1295.
- Ljungberg B., et al. (2015). Renal cell carcinoma guidelines: the 2015 update. *European Urology* 67(5): 913-924.
- Heng D.Y.C., et al. (2009). External validation of the International Metastatic Renal Cell Carcinoma Database Consortium model for survival in patients with metastatic renal cell carcinoma. *European Urology* 56(1): 66-72.
- Kauffman E.C., et al. (2010). The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: a review of the literature. *Urologic Clinics of North America* 37(4): 553-563.
- Karam J.A., et al. (2016). The role of surgery in metastatic renal cell carcinoma: a review of the literature and current guidelines. *Urologic Oncology: Seminars and Original Investigations* 34(9): 396-404.
- Motzer R.J., et al. (2013). Overall survival and clinical outcomes with pazopanib versus sunitinib in metastatic renal cell carcinoma: a randomized phase 3 trial. *Lancet* 378(9807): 1931-1939.
- Znaor A., et al. (2015). Trends in renal cell carcinoma incidence and mortality in Europe: a population-based study. *European Journal of Cancer* 51(12): 1740-1750.
